Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Nelson Hayes

Showing results (151-160 of 161) with videos related to

Pageof 17
Sort By:
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 28, 2015
Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case reportMasataka Tsuge, Akira Hiramatsu, Fumi Shinohara, et al.
Journal of Medical Virology|July 18, 2018
Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis CKei Morio, Michio Imamura, Yoshiiku Kawakami, et al.
Internal Medicine (Tokyo, Japan)|October 22, 2020
Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive ProceduresYuno Nishida, Tomokazu Kawaoka, Michio Imamura, et al.
BMC Gastroenterology|June 28, 2023
Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort studyYusuke Johira, Takashi Nakahara, Takahiro Kinami, et al.
Journal of Gastroenterology|December 24, 2013
Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis CHatsue Fujino, Michio Imamura, Yuko Nagaoki, et al.
Journal of Gastroenterology|May 31, 2017
Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapyKazuhiko Masuda, Atsushi Ono, Hiroshi Aikata, et al.
Journal of Gastroenterology|May 6, 2017
Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapyKazuhiko Masuda, Atsushi Ono, Hiroshi Aikata, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 11, 2020
Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosisKazuki Ohya, Michio Imamura, Yuji Teraoka, et al.
Japanese Journal of Clinical Oncology|October 29, 2023
Comprehensive genomic profiling testing in Japanese castration-resistant prostate cancer patients: results of a single-center retrospective cohort studyTakafumi Fukushima, Keisuke Goto, Tetsutaro Hayashi, et al.
Plos Genetics|April 18, 2013
A nonsynonymous polymorphism in semaphorin 3A as a risk factor for human unexplained cardiac arrest with documented ventricular fibrillationYukiko Nakano, Kazuaki Chayama, Hidenori Ochi, et al.
Pageof 17

Showing results (151-160 of 161) with videos related to

Sort By:
Pageof 17
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 28, 2015
Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case reportMasataka Tsuge, Akira Hiramatsu, Fumi Shinohara, et al.
Journal of Medical Virology|July 18, 2018
Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis CKei Morio, Michio Imamura, Yoshiiku Kawakami, et al.
Internal Medicine (Tokyo, Japan)|October 22, 2020
Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive ProceduresYuno Nishida, Tomokazu Kawaoka, Michio Imamura, et al.
BMC Gastroenterology|June 28, 2023
Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort studyYusuke Johira, Takashi Nakahara, Takahiro Kinami, et al.
Journal of Gastroenterology|December 24, 2013
Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis CHatsue Fujino, Michio Imamura, Yuko Nagaoki, et al.
Journal of Gastroenterology|May 31, 2017
Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapyKazuhiko Masuda, Atsushi Ono, Hiroshi Aikata, et al.
Journal of Gastroenterology|May 6, 2017
Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapyKazuhiko Masuda, Atsushi Ono, Hiroshi Aikata, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 11, 2020
Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosisKazuki Ohya, Michio Imamura, Yuji Teraoka, et al.
Japanese Journal of Clinical Oncology|October 29, 2023
Comprehensive genomic profiling testing in Japanese castration-resistant prostate cancer patients: results of a single-center retrospective cohort studyTakafumi Fukushima, Keisuke Goto, Tetsutaro Hayashi, et al.
Plos Genetics|April 18, 2013
A nonsynonymous polymorphism in semaphorin 3A as a risk factor for human unexplained cardiac arrest with documented ventricular fibrillationYukiko Nakano, Kazuaki Chayama, Hidenori Ochi, et al.
Pageof 17